These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33514572)
1. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study. Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572 [TBL] [Abstract][Full Text] [Related]
2. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416 [TBL] [Abstract][Full Text] [Related]
3. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys. Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237 [No Abstract] [Full Text] [Related]
4. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug. Sharif NA Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan. Miki A; Miyamoto E; Ishida N; Shii D; Hori K; Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233 [TBL] [Abstract][Full Text] [Related]
6. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan. Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890 [TBL] [Abstract][Full Text] [Related]
7. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. Ferro Desideri L; Cutolo CA; Barra F; Ferrero S; Traverso CE Drugs Today (Barc); 2019 Jun; 55(6):377-384. PubMed ID: 31250842 [TBL] [Abstract][Full Text] [Related]
8. Changes in Prostaglandin-associated Periorbital Syndrome After Switch from Conventional Prostaglandin F2α Treatment to Omidenepag Isopropyl in 11 Consecutive Patients. Nakakura S; Terao E; Fujisawa Y; Tabuchi H; Kiuchi Y J Glaucoma; 2020 Apr; 29(4):326-328. PubMed ID: 31913226 [TBL] [Abstract][Full Text] [Related]
9. Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval. Duggan S Drugs; 2018 Dec; 78(18):1925-1929. PubMed ID: 30465134 [TBL] [Abstract][Full Text] [Related]
10. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis. Sakata R; Fujishiro T; Saito H; Nakamura N; Honjo M; Shirato S; Miyamoto E; Yamada Y; Aihara M Jpn J Ophthalmol; 2021 Sep; 65(5):591-597. PubMed ID: 34283308 [TBL] [Abstract][Full Text] [Related]
11. One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma. Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Nozaki N; Shimizu K; Ishida K; Tomita G J Ocul Pharmacol Ther; 2022 Jun; 38(5):354-358. PubMed ID: 35613407 [No Abstract] [Full Text] [Related]
12. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study). Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861 [No Abstract] [Full Text] [Related]
13. Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma. Sakata R; Fujishiro T; Saito H; Nakamura N; Honjo M; Shirato S; Miyamoto E; Yamada Y; Aihara M J Ocul Pharmacol Ther; 2023; 39(1):63-69. PubMed ID: 36318495 [No Abstract] [Full Text] [Related]
14. Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report. Nakamoto K; Shiratori N; Nishio Y; Sugimoto S; Takano Y; Yamazaki M; Tobita Y; Igarashi T; Takahashi H J Nippon Med Sch; 2021 Nov; 88(5):506-508. PubMed ID: 33692292 [TBL] [Abstract][Full Text] [Related]
15. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Schachar RA; Raber S; Courtney R; Zhang M Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167 [TBL] [Abstract][Full Text] [Related]
16. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. Fuwa M; Toris CB; Fan S; Taniguchi T; Ichikawa M; Odani-Kawabata N; Iwamura R; Yoneda K; Matsugi T; Shams NK; Zhang JZ J Ocul Pharmacol Ther; 2018 Sep; 34(7):531-537. PubMed ID: 29989843 [TBL] [Abstract][Full Text] [Related]
17. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. Iwamura R; Tanaka M; Okanari E; Kirihara T; Odani-Kawabata N; Shams N; Yoneda K J Med Chem; 2018 Aug; 61(15):6869-6891. PubMed ID: 29995405 [TBL] [Abstract][Full Text] [Related]
18. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma. Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Kang J; Uraki T; Tomita G; Ishida K Jpn J Ophthalmol; 2024 May; 68(3):206-210. PubMed ID: 38587788 [TBL] [Abstract][Full Text] [Related]
19. One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome After Switch From Conventional Prostaglandin F2alfa to Omidenepag Isopropyl. Oogi S; Nakakura S; Terao E; Fujisawa Y; Tabuchi H; Kiuchi Y Cureus; 2020 Aug; 12(8):e10064. PubMed ID: 33005498 [TBL] [Abstract][Full Text] [Related]